Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10042170 | 0.84 | MAPK14 (0.41) | SYKMAPK14 | |
| SCHEMBL396650 | 0.81 | S1PR4 (0.41) | S1PR4SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL30745406 | 0.81 | S1PR4 (0.59) | S1PR4SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL397285 | 0.79 | S1PR4 (0.36) | S1PR4SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL30745344 | 0.78 | MRGPRX4 (0.45) | S1PR4SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL7062239 | 0.73 | — | — | |
| SCHEMBL31420239 | 0.73 | — | — | |
| SCHEMBL23251387 | 0.71 | TSHR (0.47) | SMN1; SMN2MAPTTP53KMT2AMEN1 | |
| SCHEMBL398806 | 0.71 | NPC1 (0.31) | SMN1; SMN2NPC1RAB9AMAPTLMNA | |
| SCHEMBL17150071 | 0.69 | SLC6A4 (0.43) | S1PR4MAPTL3MBTL1HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2043646-B1 | (E)-N-{3-(8-Chloro-11H-10-oxa-1-aza- dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-phenyl} -methanesulfonamide as a GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | LILLY CO ELI (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8101760-B2 | Glucocorticoid receptor modulator and methods of use | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100069425-A1 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2008008882-A2 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069425-A1 | GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE | NR3C1, NR3C2, MC2R | S1PR4 203/4885SMN1; SMN2 4203/4885NPC1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.